Phase 3 N=165 Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis
Cirrhosis
Primary: Mortality From Liver Failure — 11 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=124 Safety Study of a Sensitive Sensual Touch and Personal Lubricant
Inadequate Lubrication
Primary: Number of Participants With Physical Irritation Scores — 61; 61; 1; 0 Participants
N/A N=1,261 Survey of Osteoarthritis Real World Therapies (MK-0663-140)
Osteoarthritis
Primary: Percentage of Participants Who Reported Adequate vs. Inadequate Pain Relief at Baseline — 46.2; 53.8 Percentage of Participants
Phase 3 N=287 DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With the Indicated Device Preference Based on the Size of the Numbers on the Dose Counter — 107; 86; 23; 34 participants — p=<0.001
N/A N=36 Yoga for Managing Knee Osteoarthritis in Older Women: a Feasibility Study
Osteoarthritis, Knee · Quality of Life · Poor Quality Sleep
Primary: Absolute Value of OA Symptoms at 8 Weeks — 39.3; 31.0 units on a scale
Phase 3 N=1,532 A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) — 0.004; 0.119; 0.076; 0.171 Liters — p=<0.001
Phase 3 N=51 A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg
Cirrhosis
Primary: Body Weight — -0.76; -2.97; -0.05 Kg
Phase 4 N=232 The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
BPH
Primary: Primary Outcome; International Prostate Symptom Score Changes Between 4 Groups Compared to Baseline After 12 mo Treatment — 13.0; 12.0; 10.6; 13.4 score — p=<0.05
Phase 2 N=85 The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
Hypercholesterolemia
Primary: Percent Change in LDL-C at 12 Weeks Therapy Compared to Baseline Between Treatments — -46.2; -29.9; -19.6 Percent Change
Phase 2 N=27 Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)
Lung Cancer
Primary: Median Progression Free Survival (PFS) — 7.5 months
Phase 2 N=176 GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Day 15 of Each Treatment Period — -0.047; 0.081; 0.099; 0.048 Liters — p=<0.001
Phase 3 N=31 Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis
Osteoporosis
Primary: Change in Spine Bone Density — 6.95; 3.76; 5.68 % change in LS BMD
Phase 3 N=101 Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)
Hypertension
Primary: Mean Change From Baseline in Systolic Blood Pressure — -7.31; -7.65; -6.67 mmHg — p=0.753
N/A N=105 Cell Mediated Immunity in Older Adults
Immunity to Influenza Vaccine
Primary: Cellular Immune Response — 0.239; 0.137; 0.243; 0.160 percentage of Stimulated cells
Phase 4 N=80 Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®
Paget's Disease of the Bone · Hypocalcemia
Primary: Percentage of Patients With Serum Calcium <2.07 mmol/L at 9-11 Days After Receiving Zoledronic Acid. — 1.3; 0.0 percentage of patients